CERES BRAIN Therapeutics’ Post

At BioHouston, we're more than just a resource; we're a dynamic ecosystem where Biotech and MedTech companies converge to scale their technologies and businesses. Connect with like-minded innovators, exchange insights, and propel your venture to new heights.   Together, we're building a future where both Biotech and MedTech thrive.   #BioHouston #LifeScienceCommunity #InnovationEcosystem

🌟 Exciting News! 🌟 We are thrilled to announce that gMendel® has been selected by the Eureka Investment Readiness Program (IRP) as one of the companies to participate in their strategic initiatives! This prestigious program is part of the EU’s Innovative SME Partnership, co-funded by the European Commission. We will be participating in two International Missions: ·  Singapore Week of Innovation and Technology (SWITCH): Oct 28-30 ·  Web Summit Lisbon: Nov 11-14 These events will provide us with invaluable opportunities to deepen our understanding of global innovation ecosystems, connect with investors, and explore new market opportunities. Eureka, a pioneer in funding international R&D projects since 1985, continues to play a critical role in fostering global innovation. We are proud to be part of this journey, and this recognition reaffirms the quality of our technology and our commitment to excellence. Our CEO and co-founder, Chris Kyriakidis, shared his excitement: “This selection boosts our confidence as we keep exploring new avenues for funding and growth.” Stay tuned for more updates as we embark on these exciting ventures! #HealthTech #Genomics #Genetics #RareDiseases #GeneticDisorders #Screening #Diagnostics #Healthcare #Innovation #Growth #AI #ArtificialIntelligence #MachineLearning #CompanionDiagnostics #VC #VentureCapital Eureka Network

🔍 Medtech at a Turning Point 🔍 TVM Capital Life Science’s Managing Partner, Dr. Luc Marengere, recently shared insights with Shani Alexander of BioWorld MedTech at LSI Europe '24 on the state of the medtech sector—medtech is indeed at a pivotal moment. 💬 "The entire ecosystem is coming together. It’s not just about technologies; you need investors and buyers creating a healthier, more viable industry. Now, we’re seeing companies valued at biotech levels and exciting opportunities for investment," says Luc. With over $900M under management, TVM is proud to support companies transforming patient care and medtech innovation. Notable investments, such as TVM’s support of Access Vascular, Inc. CSA Medical Inc, Kent Imaging and Vektor Medical, Inc. Medical reflect our commitment to fostering solutions that deliver tangible patient outcomes and redefine treatment pathways. As Luc notes, these are "truly transformational opportunities"—and the future is bright for medtech. Read the full article here (pay wall): https://lnkd.in/eWMrydRb #MedTech #HealthcareInnovation #VentureCapital #LifeSciences #MedTechDeals #InvestmentOpportunities

ℹ️ LSI Europe '24 is back! Mercia Ventures is pleased to share that our Investment Director, Robert Hornby will be part of a panelist discussion speaking on US Market Access: Considerations and Strategies for OUS Companies. Held this year in Sintra, Portugal, the event is designed from the ground up to facilitate real relationships and help Medtech and Healthtech leaders accelerate their growth. If you're attending, make sure to connect with Rob who will be more than happy to chat about internationalisation, and how Mercia Ventures can support your business growth. Event link in comments ⏬ #LSIAlumni #Medtech #Healthtech #Internationalisation #Growth

ℹ️ LSI Europe '24 is back! Mercia Ventures is pleased to share that our Investment Director, Robert Hornby will be part of a panelist discussion speaking on US Market Access: Considerations and Strategies for OUS Companies. Held this year in Sintra, Portugal, the event is designed from the ground up to facilitate real relationships and help Medtech and Healthtech leaders accelerate their growth. If you're attending, make sure to connect with Rob who will be more than happy to chat about internationalisation, and how Mercia Ventures can support your business growth. Event link in comments ⏬ #LSIAlumni #Medtech #Healthtech #Internationalisation #Growth

T-minus 6 days and counting! 🚀 Looking forward to gaining insights on fostering strategic alliances at #SwissBiotechDay! Join the panel discussion to explore how innovative partnerships drive biotech forward. @SwissBiotechAssociation #IworkforCSL #SwissBiotechDay #BiotechInnovation #StrategicPartnerships

🚀 Big news! We signed a strategic partnership with Ruđer Bošković Institute to take their research and innovations from the lab to the next level by turning them into real-world solutions. This collaboration is all about bridging the gap between science and industry. Together, we’ll support projects with high potential, helping them go from ideas in the lab to products on the market. The goal? To create new opportunities for job creation, economic growth, and sustainability. 🔑 What does this mean? · IRB and Vesna VC will work hand-in-hand to support high-potential projects. · Together, we’ll facilitate market entry for new legal entities. · Intellectual property transfer and licensing agreements will ensure that technologies developed at IRB make a tangible impact on the economy and society. 🌟 This is an important step forward, opening doors for new commercial opportunities, further strengthening our science-to-market pipeline, and contributing to the growth of deep tech projects across the region. #innovation #deeptech #commercialization #partnership #science #technology #RuđerBoškovićInstitute #VesnaCapital #growth

We're thrilled to announce that our CEO, Mika Newton, will be a speaker at the upcoming Bio-IT World Investor Conference. Mika will participate in a panel discussion titled "Empowering Innovation: Build vs. Buy in Data Science and Engineering." 🔍 𝗣𝗮𝗻𝗲𝗹 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: This engaging session will dive deep into biotech investment strategies, spotlighting the role of data science in the success of startups and the strategic decision-making in larger pharmaceutical companies. It's an opportunity to explore the dynamics between developing in-house expertise versus leveraging external partnerships, the impact of outsourcing, and how technology assets are valued within the biotech/pharma landscape. A conversation for investors focused on fostering growth in this sector. 📅 𝗠𝗮𝗿𝗸 𝗬𝗼𝘂𝗿 𝗖𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀! Date: April 17, 2024 Time: 12:00 PM EST Omni Boston Hotel at the Seaport Boston, MA 🎙️ 𝗙𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴 𝗘𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝗣𝗮𝗻𝗲𝗹𝗶𝘀𝘁𝘀: Dana Callow, Founder & Managing Partner, Boston Millennia Partners Tom Neyarapally, CEO and Co-Founder, Archetype Therapeutics, Inc. Miruna Sasu, President and CEO, COTA, Inc. Christina Vorvis, PhD, Director, AbbVie Ventures Xiaoying Wu, MD,MS, Vice President, Data Science & Digital Health, Johnson & Johnson Innovative Medicine Mika and the team of experts will provide important insights that promise to enrich our understanding of innovation management in the health sector. For more details on the panel and the event, visit: https://lnkd.in/dRnKKURy If you are attending the Bio-IT World Conference & Expo and want to learn more about the xCures Platform, feel free to contact Bryan Federowicz, who will be at the event. #BioITWorld #InvestorConference #DataScience #Biotech #PharmaInnovation #HealthTech

Biotech startups - how is your relationship with your investors? Join our co-founder and CEO, Kristian Tryggvason, as he forms part of a panel discussion at the LSX Nordic Congress in Copenhagen on the 8th October. Entitled "VCs & Startups: Allies or Opponents in the Startup Journey?," the panel aims to openly and honestly discuss the 𝘃𝗶𝘁𝗮𝗹 𝘆𝗲𝘁 𝘁𝗲𝗻𝘁𝗮𝘁𝗶𝘃𝗲 𝗿𝗲𝗹𝗮𝘁𝗶𝗼𝗻𝘀𝗵𝗶𝗽 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗳𝗶𝗿𝘀𝘁-𝘁𝗶𝗺𝗲 𝗖𝗘𝗢𝘀 𝗮𝗻𝗱 𝗻𝗼𝗻-𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀: - What drives the relationship? - What are common pitfalls (and how can we negotiate them)? - Mending (and growing) strained relationships Come hear what nuggets of truth Kristian and his co-panellists have to share. In anticipation of the interesting discussions on the day, why not 𝘀𝗵𝗮𝗿𝗲 𝗬𝗢𝗨𝗥 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀 with us? Simply comment below - we'd love to hear from you.  Alternatively, why not set aside some time to 𝗺𝗲𝗲𝘁 𝘄𝗶𝘁𝗵 𝗞𝗿𝗶𝘀𝘁𝗶𝗮𝗻 at the event? Comment below on a suitable time, or DM Kristian directly. https://lnkd.in/eCkHc4Rq #LSXNordic #BioTech #Funding #Venturecapital

What unique challenges do early stage companies face when they’re focusing on bioconvergence technologies? In this clip, Assaf Barnea, CEO of Sanara Ventures, emphasizes that this convergence is not just about blending novel technologies but also about uniting diverse experts from various fields. While this integration poses challenges, it’s an essential hurdle to overcome. The synergy between different people and technologies brings disruptive innovations to the space. Our latest #LSIUSA24 panel, ‘Bioconvergence: Breaking Down Silos in Disruptive Innovation’, defines the "bioconvergence" happening in healthcare, explores fresh opportunities in this segment, and highlights what it means for the future of the industry. Hear from: • Marc Alcser (Moderator) — Stradling Yocca Carlson & Rauth LLP • Assaf Barnea — Sanara Ventures • Ariane Tom, PhD — Kaleida Capital • Suraj Mudichintala — Action Potential Venture Capital 🔗 Watch full panel here: https://lnkd.in/ddy4F_x8 Want to see more content like this? Registration and applications to present are open for LSI Europe ‘24 this September 16th - 20th at the Penha Longa Resort, in Portugal. Secure your spot today to ensure you get the best rate and secure a hotel room onsite.